Zim Laboratories Ltd. (IN:ZIMLAB)
:ZIMLAB
Want to see IN:ZIMLAB full AI Analyst Report?
Top Page
Zim Laboratories Ltd.
(ZIMLAB)
Select Model
Select Model
Rating:60Neutral
Price Target:
₹105.00
▲(47.66% Upside)
Action:Reiterated
Date:05/21/26
The score is supported by strong technical trend and momentum, but is held back by weakening recent profitability and volatile cash generation with negative free cash flow in FY2026. Valuation appears moderate based on the provided P/E, with no dividend yield data to add support.
Positive Factors
Balance sheet equity growth
Rising equity over FY2025–FY2026 expands the company’s capital base and cushions leverage, improving financial flexibility. A stronger equity position supports longer-term investments, partnership negotiations and resilience to cyclical downturns without immediate reliance on external debt.
Negative Factors
Negative and volatile free cash flow
Return to negative free cash flow in FY2026 signals weaker cash available after investments, reflecting working-capital swings or higher capex. Persistently negative FCF erodes the company’s ability to self-fund expansion, repay debt, or return capital, raising structural financing risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet equity growth
Rising equity over FY2025–FY2026 expands the company’s capital base and cushions leverage, improving financial flexibility. A stronger equity position supports longer-term investments, partnership negotiations and resilience to cyclical downturns without immediate reliance on external debt.
Read all positive factors
Zim Laboratories Ltd. (ZIMLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹5.35B
Dividend YieldN/A
Average Volume (3M)6.28K
Price to Earnings (P/E)19.8
Beta (1Y)1.07
Revenue Growth-1.22%
EPS Growth-52.32%
CountryIN
Employees556
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.35
Shares Outstanding53,549,038
10 Day Avg. Volume5,950
30 Day Avg. Volume6,279
Financial Highlights & Ratios
PEG Ratio-0.97
Price to Book (P/B)1.00
Price to Sales (P/S)0.79
P/FCF Ratio-39.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zim Laboratories Ltd. Business Overview & Revenue Model
Company Description
ZIM Laboratories Limited develops, manufactures, and supplies pharmaceutical formulation and pre formulation ingredients in India and internationally. The company provides technology-based drug delivery solutions and non-infringing proprietary man...
How the Company Makes Money
Zim Laboratories primarily makes money by selling pharmaceutical finished-dosage products. Key revenue streams include: (1) Branded/portfolio sales: revenue from marketing and selling its own formulations (including differentiated oral drug-delive...
Zim Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
66
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.66B | 3.74B | 3.74B | 3.68B | 3.99B | 3.31B |
| Gross Profit | 1.85B | 1.25B | 730.04M | 1.86B | 903.81M | 1.67B |
| EBITDA | 431.55M | 300.10M | 495.11M | 454.76M | 582.00M | 452.62M |
| Net Income | 65.86M | 58.38M | 121.65M | 172.46M | 244.34M | 145.50M |
Balance Sheet | ||||||
| Total Assets | 4.70B | 5.39B | 4.72B | 4.47B | 3.42B | 3.42B |
| Cash, Cash Equivalents and Short-Term Investments | 50.12M | 434.13M | 20.37M | 96.41M | 64.66M | 34.20M |
| Total Debt | 1.23B | 1.26B | 1.18B | 1.12B | 620.00M | 533.14M |
| Total Liabilities | 2.19B | 2.43B | 2.20B | 2.08B | 1.41B | 1.66B |
| Stockholders Equity | 2.51B | 2.96B | 2.52B | 2.39B | 2.00B | 1.76B |
Cash Flow | ||||||
| Free Cash Flow | 40.45M | -75.72M | 3.57M | -576.45M | 15.00M | 339.81M |
| Operating Cash Flow | 199.18M | 368.15M | 411.55M | 162.78M | 381.68M | 492.06M |
| Investing Cash Flow | -155.70M | -565.23M | -399.27M | -730.13M | -362.04M | -145.71M |
| Financing Cash Flow | -34.19M | 410.81M | -91.05M | 595.34M | 5.46M | -329.70M |
Zim Laboratories Ltd. Technical Analysis
Positive
71.11
Price Trends
79.18
Positive
75.49
Positive
75.66
Positive
Market Momentum
6.39
Positive
62.07
Neutral
27.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ZIMLAB, the sentiment is Positive. The current price of 71.11 is below the 20-day moving average (MA) of 94.55, below the 50-day MA of 79.18, and below the 200-day MA of 75.66, indicating a bullish trend. The MACD of 6.39 indicates Positive momentum. The RSI at 62.07 is Neutral, neither overbought nor oversold. The STOCH value of 27.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ZIMLAB.
Zim Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹13.95B | 10.01 | ― | ― | 7.99% | 119.03% | |
60 Neutral | ₹5.35B | 19.82 | ― | ― | -1.22% | -52.32% | |
59 Neutral | ₹2.11B | -338,564.26 | ― | ― | 0.76% | -116.54% | |
55 Neutral | ₹4.01B | -224.07 | ― | 0.66% | -3.52% | -108.70% | |
55 Neutral | ₹3.69B | 56.53 | ― | 0.26% | -7.50% | 6.39% | |
52 Neutral | ₹2.74B | 7.63 | ― | ― | -57.41% | -2188.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ZIMLAB
Zim Laboratories Ltd.
100.00
8.69
9.52%
IN:ALBERTDAVD
Albert David Ltd
706.50
-101.72
-12.59%
IN:LYKALABS
Lyka Labs Limited
61.42
-57.18
-48.21%
IN:MEDICAMEQ
Medicamen Biotech Limited
267.85
-161.16
-37.57%
IN:NECLIFE
Nectar Lifesciences Ltd.
12.39
-11.45
-48.03%
IN:VENUSREM
Venus Remedies Limited
1,031.40
676.60
190.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.